Annuncio • Mar 27
Numinus Wellness Provides Update Regarding Listing Status Numinus Wellness Inc. is providing an update regarding its listing status on the Toronto Stock Exchange ("TSX"). As previously disclosed in the Company's management information circular dated July 29, 2025, and as approved by shareholders at the Company's annual general meeting held on August 28, 2025 (with voting results subsequently disclosed on September 3, 2025), shareholders authorized the Board of Directors, in its discretion, to voluntarily delist the Company's common shares from the TSX if deemed to be in the best interests of the Company. Further to Numinus' news release of March 13, 2026, on March 19, 2026 the Continued Listing Committee of the TSX met and determined to delist the Company's common shares from the TSX, effective April 22, 2026. While this delisting does not result from a request from the Company, it is consistent with the authorization of the shareholders to delist Numinus from the TSX, and aligns with the Company's previously disclosed strategic considerations. As the Company remains subject to a cease trade order (the "CTO"), the delisting from the TSX will not change the current trading status of its securities, which are not presently tradable in Canada. The Company will continue to be a reporting issuer in all applicable Canadian jurisdictions. Looking ahead for Numinus, management is pleased to advise that an application has been filed to list the Company's shares on the Canadian Securities Exchange (the "CSE"). If approved, a listing on the CSE could only take effect after the CTO has been revoked. The listing of the Company's common shares on the CSE is subject to the Company meeting the CSE's listing requirements, which cannot be guaranteed. Management remains focused on: completing the work to have the audit completed for the Company's financial statements for the year ended August 31, 2026; satisfying all regulatory requirements necessary to have the CTO revoked; and advancing an application to list its common shares on the CSE. Successfully executing these steps remains management's primary strategy to restore trading, enhance shareholder liquidity, and position the Company for its next phase of growth. Annuncio • Jul 14
Numinus Wellness Inc., Annual General Meeting, Aug 28, 2025 Numinus Wellness Inc., Annual General Meeting, Aug 28, 2025. Annuncio • Dec 18
Stella MSO, Inc. completed the acquisition of Five Wellness Clinics from Numinus Wellness Inc. (TSX:NUMI). Stella MSO, Inc. signed a definitive agreement to acquire Five Wellness Clinics from Numinus Wellness Inc. (TSX:NUMI) for $3.5 million on November 15, 2024. A cash consideration of $2.08 million will be paid by Stella MSO, Inc. Stella MSO, Inc. will pay a deferred payment of $0.75 million cash paid over six equal monthly instalments in 2025 and of $0.7 million cash to be paid in 2025. The transaction is expected to close on or before November 30, 2024.
Stella MSO, Inc. completed the acquisition of Five Wellness Clinics from Numinus Wellness Inc. (TSX:NUMI) on December 17, 2024. Breakeven Date Change • Jul 15
Forecast to breakeven in 2026 The analyst covering Numinus Wellness expects the company to break even for the first time. New forecast suggests the company will make a profit of CA$430.0k in 2026. Average annual earnings growth of 75% is required to achieve expected profit on schedule. Reported Earnings • Jul 14
Third quarter 2024 earnings released: CA$0.019 loss per share (vs CA$0.028 loss in 3Q 2023) Third quarter 2024 results: CA$0.019 loss per share (improved from CA$0.028 loss in 3Q 2023). Revenue: CA$4.35m (down 28% from 3Q 2023). Net loss: CA$5.12m (loss narrowed 30% from 3Q 2023). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Annuncio • Jul 11
Numinus Wellness Inc. to Report Q3, 2024 Results on Jul 11, 2024 Numinus Wellness Inc. announced that they will report Q3, 2024 results After-Market on Jul 11, 2024 Annuncio • Jun 08
Numinus Wellness Comments on FDA Advisory Committee Meeting for Investigational MDMA-Assisted Therapy for PTSD Numinus Wellness Inc. comments on the results of June 4, 2024 meeting of the U.S. Food and Drug Administration's ("FDA") Psychopharmacologic Drugs Advisory Committee ("PDAC"). The independent committee reviewed Lykos Therapeutics' new drug application for MDMA (midomafetamine capsules) used in combination withpsychological intervention for individuals with post-traumatic stress disorder ("PTSD"). The PDAC voted against recommending approval of MDMA for PTSD in a majority decision where 2 of 11 found that the available data demonstrates MDMA's effectiveness in PTSD patients, and one committee member found that the benefits of MDMA outweigh its risks for treating PTSD patients based on available data. The FDA is expected to decide on Lykos' new drug application in August this year and is not bound by the PDAC's guidance. Advisory committees, like PDAC, make non-binding recommendations to the FDA. Historically, between 2010 and 2021, the FDA approved subject treatments in 97% of cases where the committee recommended approval and in 33% of cases where the committee recommended against approval. 1 There can be no assurance as to the FDA's decision with respect to Lykos' MDMA new drug application. Pending the approval of new medications for the treatment of mental health conditions, Spravato® (esketamine), and ketamine continue to be available to practitioners. The Numinus US clinic network has delivered over 43,600 such treatments to patients. Through the auspices of Health Canada's Special Access Program, Numinus clinics have also treated several patients with MDMA and psilocybin in Canada. Through Cedar Clinical Research, Numinus has conducted clinical research involving four psychedelic medicines administered through different modalities involving 50 subjects over the past 2.5 years. At the same time, company's comprehensive practitioner training program prepares the Numinus team and trainees to treat patients across multiple medications and modalities, including ketamine and MDMA. Annuncio • May 30
Numinus Wellness Receives Health Canada Approval for Study into Group Model for MDMA-Assisted Therapy Numinus Wellness Inc. announced that Health Canada has approved the Company's Clinical Trial Application to examine the feasibility of a group model in MDMA-assisted psychotherapy enrolling trainee practitioners as participants. The study aims to enhance comprehension of the ideal number of therapists needed to administer MDMA-assisted psychotherapy group sessions effectively. Additionally, the trial offers eligible trainees the chance to develop core competencies through observing seasoned therapists conduct MDMA-assisted psychotherapy sessions and legally experience MDMA themselves in a therapeutic setting as healthy research subjects. The clinical trial is formally titled "Phase 1 Exploration of Feasibility and Optimal Therapist Numbers in Group Model MDM-Assisted Psychotherapy: A Study on Safety, Delivery, and Practitioner Training. Reported Earnings • Apr 14
Second quarter 2024 earnings released: CA$0.023 loss per share (vs CA$0.028 loss in 2Q 2023) Second quarter 2024 results: CA$0.023 loss per share (improved from CA$0.028 loss in 2Q 2023). Revenue: CA$5.03m (down 6.0% from 2Q 2023). Net loss: CA$5.95m (loss narrowed 19% from 2Q 2023). Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings. Annuncio • Apr 10
Numinus Wellness Inc. to Report Q2, 2024 Results on Apr 15, 2024 Numinus Wellness Inc. announced that they will report Q2, 2024 results After-Market on Apr 15, 2024 Annuncio • Mar 20
Numinus Wellness Inc. Submits Clinical Trial Application Numinus Wellness Inc. announced that it has submitted a Clinical Trial Application to Health Canada to examine the feasibility of a group model in MDMA-assisted psychotherapy enrollee practitioners as participants. If approved, the trial would allow Numinus to study MDMA-assisted psychotherapy with groups and better understand the optimum number of therapists required to deliver the programs safely. It may also provide eligible trainees with the opportunity to build core competencies and legally experience MDMA. The clinical trial is formally titled Phase 1 Exploration of Feasibility and Optimal Therapist Numbers in Group Model MDM-Assisted Psychotherapy: A Study on Safety, Delivery, and Practitioner Training. If approved, it will be the first of its kind. Annuncio • Feb 16
Numinus Wellness Inc. has completed a Composite Units Offering in the amount of CAD 6 million. Numinus Wellness Inc. has completed a Composite Units Offering in the amount of CAD 6 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 50,000,000
Price\Range: CAD 0.12 Reported Earnings • Jan 16
First quarter 2024 earnings released: CA$0.02 loss per share (vs CA$0.024 loss in 1Q 2023) First quarter 2024 results: CA$0.02 loss per share (improved from CA$0.024 loss in 1Q 2023). Revenue: CA$5.95m (up 4.9% from 1Q 2023). Net loss: CA$4.41m (loss narrowed 30% from 1Q 2023). Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings. Annuncio • Dec 19
Numinus Wellness Inc., Annual General Meeting, Feb 26, 2024 Numinus Wellness Inc., Annual General Meeting, Feb 26, 2024. Board Change • Dec 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Member of the Clinical Advisory Council Pam Kryskow was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Dec 01
Full year 2023 earnings released: CA$0.12 loss per share (vs CA$0.17 loss in FY 2022) Full year 2023 results: CA$0.12 loss per share (improved from CA$0.17 loss in FY 2022). Revenue: CA$23.2m (up 257% from FY 2022). Net loss: CA$30.3m (loss narrowed 33% from FY 2022). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings. Annuncio • Nov 22
Numinus Wellness Inc. to Report Q4, 2023 Results on Nov 29, 2023 Numinus Wellness Inc. announced that they will report Q4, 2023 results After-Market on Nov 29, 2023 Annuncio • Oct 05
Numinus Wellness Inc. Introduces Its Innovative and Comprehensive Psychedelic Program for Individuals Surging from Mental Distress Associated with Chronic and Serious Illness Through Cedar Clinical Research Numinus Wellness Inc. introduced its innovative and comprehensive psychedelic program for individuals suffering from mental distress associated with serious and chronic illness. Operating out of the Numinus Wellness UT and Cedar Clinical Research facilities, the program encompasses four key initiatives that showcase Numinus' commitment to advancing psychedelic research and its potential for healing. Group Psilocybin Pilot Study Numinus Chief Science Officer, Dr. Paul Thielking, is the senior author of a recently published study of the safety, feasibility, and possible efficacy of group-administered psilocybin for depressed cancer patients. This study not only demonstrates the possible therapeutic benefits of psilocybin but also highlights the immense potential the group model holds for reducing the costs associated with psychedelic therapy. Numinus has also completed a group ketamine-assisted therapy intervention pilot for subjects suffering from chronic and serious illnesses. This pilot project showcased the effectiveness of ketamine-assisted therapy in alleviating depression and psychological distress associated with these conditions. This endeavor underscores Numinus' commitment to exploring innovative psychedelic-assisted therapy models for patients in need of new treatment options. Group Psilocybin Project Building on the success of the ketamine pilot project and the group psilocybin study, Numinus is thrilled to announce an upcoming follow-up group psilocybin project. Approved by both the U.S. Food and Drug Administration (FDA) and an Institutional Review Board (IRB), this study will, among other things, reduce the therapist to patient ratio while continuing to evaluate the impact of psilocybin-assisted therapy on cancer patients with depression. Subject to the availability of legal psilocybin- assisted therapy under applicable law, the results of this research may contribute to reducing costs and enhancing access for this patient population in the future. Breakeven Date Change • Aug 31
Forecast to breakeven in 2026 The analyst covering Numinus Wellness expects the company to break even for the first time. New forecast suggests the company will make a profit of CA$8.81m in 2026. Average annual earnings growth of 63% is required to achieve expected profit on schedule. Reported Earnings • Jul 18
Third quarter 2023 earnings released: CA$0.028 loss per share (vs CA$0.033 loss in 3Q 2022) Third quarter 2023 results: CA$0.028 loss per share. Revenue: CA$6.03m (up CA$5.29m from 3Q 2022). Net loss: CA$7.29m (loss widened 4.0% from 3Q 2022). Revenue is forecast to grow 39% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Pharmaceuticals industry in Germany. Annuncio • Jun 30
Numinus Wellness Inc. to Report Q3, 2023 Results on Jul 17, 2023 Numinus Wellness Inc. announced that they will report Q3, 2023 results After-Market on Jul 17, 2023 Annuncio • Jun 15
Numinus Wellness Inc. Appoints Nikhil Handa as Chief Financial Officer, Effective from June 15, 2023 Numinus Wellness Inc. announced the appointment of Nikhil Handa as Chief Financial Officer, effective June 15, 2023, following a thorough executive search. Current Chief Financial Officer, John Fong, will be stepping down effective end of day to focus on family health matters. Mr. Fong will remain involved with the Company during the incoming CFO transition period to ensure a seamless transfer of responsibilities. Most recently, Mr. Handa was CFO at The Supreme Cannabis Company Inc., where he led finance, investor relations and corporate development. At Supreme, Mr. Handa led the restructuring of the company to focus on profitable growth, and was responsible for executing the sale of Supreme to Canopy Growth Corporation. Prior to this, he led finance at Well.ca, a leading digital health and wellness company. In that role he led the finance function, provided leadership across various aspects of operations and drove key strategic initiatives including the sale of Well.ca to McKesson Canada. Over the course of his career, Mr. Handa also held a variety of senior finance and operational roles at Restaurant Brands International. Mr. Handa was part of the mergers and acquisition group of RBC Capital Markets, where he helped advise the management teams and board of directors of private and public companies on various types of transactions across Canada, the U.S., and globally. Annuncio • Jun 06
Numinus Wellness Inc. Announces Cedar Clinical Research Numinus Wellness Inc. announced Cedar Clinical Research (CCR) is a top research site for MindMed's Phase 2b study evaluating MM-120 (lysergide D-tartrate) for General Anxiety Disorder. CCR's research clinic in Draper, Utah, is the top enrolling site for the research study - having enrolled and dosed 19 clinical trial participants for the study to date. CCR also recently began enrolling volunteers for this trial at a second research clinic - in Murray, Utah. The MindMed study aims to enroll up to 200 participants who will receive a single administration of 25 ug, 50 ug, 100 ug or 200 ug of MM-120 or placebo. Topline results are expected to be announced by MindMed in late 2023. Annuncio • May 31
Numinus Wellness Inc. Announces to Research COMP360 Psilocybin Therapy in Treatment-Resistant Depression as Part of Large Phase 3 Study Numinus Wellness Inc. announced that Cedar Clinical Research (CCR) has begun studying COMP360 psilocybin therapy, an investigational new therapy for treatment-resistant depression (TRD), as part of the largest-ever international clinical study of psilocybin therapy. Dr. Paul Thielking, Chief Science Officer at Numinus, and the team have begun accepting people with TRD who fulfill certain eligibility criteria to join the study. The study in Draper, Utah, is a part of COMPASS Pathway's phase 3 program in TRD. The international program is composed of two pivotal trials, each with a long-term follow-up component. It will enroll over 800 participants, with top line data expected in summer 2024 and mid-2025. The launch of the phase 3 program follows positive results from COMPASS Pathways' phase 2b trial, published in the New England Journal of Medicine, the world's leading peer-reviewed medical journal. The objective of the randomized, controlled, double-blind phase 2b study was to understand the efficacy and safety of a single dose of investigational COMP360 psilocybin (25mg or 10mg), compared to 1mg, in patients with TRD. After a single 25mg dose of COMP360 psilocybin, in combination with psychological support, 29.1% of participants with TRD were in remission by week 3. Annuncio • May 26
Numinus Wellness Inc Aligns Business Initiatives to Prepare for Future Approval of MDMA-Assisted Therapy Numinus Wellness Inc. announced several recent initiatives aimed at best positioning the company for the expected FDA approval of MDMA-assisted therapy ("MDMA-AT") in the United States in the first half of 2024. In anticipation of this regulatory approval, Numinus has undertaken several initiatives to prepare the company for a rapid rollout of MDMA-AT services (using the MAPS protocol), including the recently launched Numinus NetworkTM clinic expansion program, reallocation of resources towards revenue producing activities, cost containment initiatives, and preparation for insurance reimbursement systems. Reported Earnings • Apr 14
Second quarter 2023 earnings released: CA$0.028 loss per share (vs CA$0.038 loss in 2Q 2022) Second quarter 2023 results: CA$0.028 loss per share (improved from CA$0.038 loss in 2Q 2022). Revenue: CA$5.35m (up CA$4.57m from 2Q 2022). Net loss: CA$7.33m (loss narrowed 6.5% from 2Q 2022). Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Annuncio • Feb 02
Numinus Wellness Inc. Receives Clinical Trial Application Approval from Health Canada for Experiential Psychedelic-Assisted Therapy Training Using Psilocybe Cubensis Tea Numinus Wellness Inc. announced that it has received approval from Health Canada for its experiential training study that will test the safety and clinical efficacy of whole Psilocybe cubensis tea for therapeutic use, and enable practitioners to further their understanding of psychedelic-assisted therapy through experiential training. The clinical trial, formally titled A Phase 1, Open-Label, Single-Arm Study to Evaluate Psilocybin Experiential Training in Healthy Volunteers and Expand Knowledge and Qualifications of Therapists Planning to Conduct Psilocybin-Assisted Therapy (NUMT2), will initially be conducted at Numinus' clinic in Vancouver, and will begin selecting volunteers in the next several weeks. Study subjects will be selected from practitioners who have trained or are currently training to provide psilocybin-assisted therapy through Numinus' Practitioner Training Program or other approved training programs. Initial results from the study are expected to be published in the second half of 2023. The protocol for the clinical trial will include three sessions per study participant: one preparatory session, one dosing session, and one integration session, which will be followed by an observation period and participant interviews and questionnaires. Over the course of the clinical trial, each experiential training study volunteer will participate both as a study participant receiving the protocol and as an observer for another participant's sessions. The clinical trial will use Numinus Bioscience's EnfiniTea, a whole mushroom Psilocybe tea product delivering 25mg of psilocybin to patients when administered as directed, for trial dosing. EnfiniTea is produced using Numinus' own validated strain of Psilocybe cubensis BP-Star, and is uniquely shelf stable, consistently dosed and economical to produce. The product has also been submitted to Health Canada to be included on the psilocybin supplier list for the federal Special Access Program, through which health care providers can apply to provide psilocybin-assisted therapy, among other psychedelic-assisted therapies, to patients with demonstrable need. Reported Earnings • Jan 17
First quarter 2023 earnings released: CA$0.024 loss per share (vs CA$0.026 loss in 1Q 2022) First quarter 2023 results: CA$0.024 loss per share. Revenue: CA$5.67m (up CA$4.88m from 1Q 2022). Net loss: CA$6.30m (loss widened 18% from 1Q 2022). Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany. Annuncio • Jan 05
Numinus Wellness Inc. to Report Q1, 2023 Results on Jan 16, 2023 Numinus Wellness Inc. announced that they will report Q1, 2023 results After-Market on Jan 16, 2023 Annuncio • Dec 20
Numinus Wellness Inc., Annual General Meeting, Feb 15, 2023 Numinus Wellness Inc., Annual General Meeting, Feb 15, 2023. Reported Earnings • Dec 01
Full year 2022 earnings released: CA$0.21 loss per share (vs CA$0.11 loss in FY 2021) Full year 2022 results: CA$0.21 loss per share (further deteriorated from CA$0.11 loss in FY 2021). Revenue: CA$6.49m (up 329% from FY 2021). Net loss: CA$44.9m (loss widened 139% from FY 2021). Revenue is forecast to grow 55% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany. Board Change • Nov 16
High number of new and inexperienced directors There are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. 1 experienced director. 1 highly experienced director. Independent Director Allen Morishita is the most experienced director on the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Jul 15
Third quarter 2022 earnings released: CA$0.033 loss per share (vs CA$0.025 loss in 3Q 2021) Third quarter 2022 results: CA$0.033 loss per share (down from CA$0.025 loss in 3Q 2021). Net loss: CA$7.01m (loss widened 45% from 3Q 2021). Over the next year, revenue is forecast to grow 550%, compared to a 7.6% growth forecast for the industry in Germany. Board Change • Apr 27
High number of new and inexperienced directors There are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. 1 experienced director. 1 highly experienced director. Independent Director Allen Morishita is the most experienced director on the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Apr 16
Second quarter 2022 earnings released: CA$0.038 loss per share (vs CA$0.028 loss in 2Q 2021) Second quarter 2022 results: CA$0.038 loss per share (down from CA$0.028 loss in 2Q 2021). Net loss: CA$7.84m (loss widened 85% from 2Q 2021). Over the next year, revenue is forecast to grow 593%, compared to a 7.8% growth forecast for the industry in Germany. Reported Earnings • Jan 21
First quarter 2022 earnings: EPS in line with expectations, revenues disappoint First quarter 2022 results: CA$0.026 loss per share (down from CA$0.017 loss in 1Q 2021). Net loss: CA$5.35m (loss widened 178% from 1Q 2021). Revenue missed analyst estimates by 1.3%. Over the next year, revenue is forecast to grow 472%, compared to a 7.1% growth forecast for the industry in Germany. Reported Earnings • Dec 10
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: CA$0.11 loss per share (up from CA$0.15 loss in FY 2020). Net loss: CA$18.8m (loss widened 96% from FY 2020). Revenue missed analyst estimates by 24%. Over the next year, revenue is forecast to grow 528%, compared to a 7.0% growth forecast for the pharmaceuticals industry in Germany. Reported Earnings • Jul 31
Third quarter 2021 earnings released: CA$0.025 loss per share (vs CA$0.035 loss in 3Q 2020) Third quarter 2021 results: Net loss: CA$4.82m (loss widened 46% from 3Q 2020). Reported Earnings • May 03
Second quarter 2021 earnings released: CA$0.028 loss per share (vs CA$0.016 loss in 2Q 2020) Second quarter 2021 results: Net loss: CA$4.24m (loss widened 435% from 2Q 2020). Reported Earnings • Feb 01
First quarter 2021 earnings released: CA$0.017 loss per share (vs CA$0.017 loss in 1Q 2020) The company reported a mediocre first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: CA$229.2k (up 71% from 1Q 2020). Net loss: CA$1.93m (loss widened 112% from 1Q 2020). Annuncio • Jan 14
Numinus Wellness Forges Forward into Psychedelic Discovery Research with the Orbitrap Exploris 120 Mass Spectometer Numinus Wellness Inc. announced it has acquired the Orbitrap Exploris 120 mass spectrometer with Vanquish Flex Binary ("Orbitrap") instrument for its continued research and development of Psilocybe mushroom related projects at Numinus Bioscience, the Company's 7,000 square foot analytics and research laboratory. Implementation of the Orbitrap, a high resolution mass spectrometry instrument, will continue the accelerated trajectory of Numinus Bioscience's research strategy to optimize cultivation, harvest, and extraction of Psilocybe mushrooms. This follows Numinus' successful completion of the first legal extraction in Canada by a public company for research and development purposes in December. Numinus Bioscience is focused on developing analytical methods and formulations for the evolving psychedelics space by establishing itself at the forefront of analytical testing for psychedelics. Use of the Orbitrap Exploris 120 will allow Numinus to accelerate psychedelic standardized testing, research and development activities for third-party clients and strategic partners, as well as high throughput testing for amenable compounds. As well, the Orbitrap will be instrumental in ensuring that dried Psilocybe Mushrooms provided for special access are safe and that the therapeutic compounds consistently meet all required specifications. This follows Health Canada's announcement of its intention to revise the Special Access Programme (SAP) to permit access to MDMA and psilocybin-assisted psychotherapy in the same way other investigational medications are accessed in Canada. Annuncio • Jan 08
Numinus Wellness Inc. Signs Lab Services Agreement with Optimi Health Corp Numinus Wellness Inc. announced that it has signed a lab services agreement with Optimi Health Corp. ("Optimi"), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, to further the research and development of Canadian-grown psilocybin-producing mushrooms. Through this first-of-its-kind agreement, Optimi will utilize and leverage Numinus Bioscience's laboratories, equipment, services and expertise, with the goal of developing products for the emerging psychedelic industry. Optimi has applied to Health Canada for a research exemption allowing it to conduct activities involving psychedelic compounds and, in advance of approval, will undertake a number of research and development projects with Numinus related to Psilocybe mushrooms, psychedelic compounds, and formulations. Under the terms of the agreement, Optimi will pay an initial retainer with fees for services determined and replenished on a project-by-project basis. Each project is expected to be a stand-alone project that is defined by a Statement of Work, and while certain projects may build upon previously completed ones, there may also be several projects undertaken at the same time. Optimi will further issue to Numinus 150,000 fully paid and non-assessable common shares in the capital of Optimi (each a "Share") on January 4, 2021 and 150,000 Shares upon completing the first project that the parties enter into. All shares will be subject to resale restrictions expiring four months and one day from their date of issue. Numinus Bioscience's laboratory provides services including cultivation, analytical testing, product research and development, and ancillary services in the area of psychedelics. The agreement with Optimi is effective January 4, 2021 and constitutes one of the first opportunities for Numinus to generate revenue from independent parties utilizing its state of the art laboratory facility, scientific expertise, and authorization to work with
controlled drugs and substances. Reported Earnings • Jan 01
Full year 2020 earnings released: CA$0.15 loss per share The company reported a solid full year result with improved revenues and control over expenses, though losses increased. Full year 2020 results: Revenue: CA$881.2k (up CA$773.7k from FY 2019). Net loss: CA$9.60m (loss widened 32% from FY 2019). Annuncio • Dec 31
Numinus Wellness Inc. has completed a Composite Units Offering in the amount of CAD 15.00012 million. Numinus Wellness Inc. has completed a Composite Units Offering in the amount of CAD 15.00012 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 22,059,000
Price\Range: CAD 0.68
Discount Per Security: CAD 0.046
Transaction Features: Rule 144A Annuncio • Dec 19
Numinus Wellness Inc. Completes First Extraction of its Psilocybe Mushrooms Numinus Wellness Inc. has completed the first legal extraction of Psilocybe mushrooms in Canada by a public company for research and development purposes. This follows Numinus' successful completion of the cultivation and harvest of the first legal flush of Psilocybe mushrooms at Numinus Bioscience, the Company's 7,000 square foot analytics and research laboratory. Numinus Bioscience is establishing itself at the forefront of analytical testing for psychedelic substances, as a centre of excellence for psychedelic product research and development, and as an ancillary for psychedelic therapy clinical trials. Health Canada licences, scientific expertise, and technologies facilitate ongoing innovation, while revenue from high-throughput contract cannabis testing is reinvested to further its psychedelic initiatives. Annuncio • Dec 17
Numinus Wellness Inc. (TSXV:NUMI) entered into an agreement to acquire Mindspace Psychology Services Inc. Numinus Wellness Inc. (TSXV:NUMI) entered into an agreement to acquire Mindspace Psychology Services Inc on December 15, 2020. The agreement of the transaction is $0.5 million in cash upon closing of the transaction, a time-based payout of 441,176 common shares of Numinus issued over the course of 24 months, $0.1 million in Numinus Shares, per year on each of the first three (3) anniversaries of the Closing Date, a multi-year performance payout of $0.8 million in Numinus shares, issued at Market Price. The closing of the Transaction is subject to a number of conditions, including the approval of the TSX Venture exchange, and is expected to be completed by December 31, 2020. Is New 90 Day High Low • Dec 15
New 90-day high: €1.42 The company is up 968% from its price of €0.13 on 16 September 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 3.0% over the same period. Annuncio • Dec 03
Numinus Wellness Inc. and Multidisciplinary Association for Psychedelic Studies Public Benefit Corporation Announces Collaboration Agreement to Seek Approval of MDMA-Assisted Psychotherapy for PTSD Single-Arm, Open-Label Trial Numinus Wellness Inc. and the Multidisciplinary Association for Psychedelic Studies Public Benefit Corporation announced a collaboration agreement that will seek approval to deliver MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD) through a single-arm, open-label, compassionate access trial. This clinical trial will be the first-of-its-kind in Canada and will take a meaningful step in furthering the accessibility of MDMA-assisted treatment options for those experiencing PTSD around the world. Through the completion of six Phase 2 trials and ongoing Phase 3 trials, MAPS and MAPS PBC have undertaken ground-breaking research demonstrating that MDMA-assisted psychotherapy — which recently received "breakthrough therapy" status from the U.S. Food and Drug Administration (FDA) — may provide sufficient benefit to patients experiencing PTSD to support approval from the FDA. This compassionate access trial, if approved, will be conducted at Numinus' Vancouver clinic, providing MDMA-assisted psychotherapy to an initial 20 individuals experiencing PTSD and collecting outcome and safety data for Health Canada. Numinus' physicians, therapists and staff will be trained to deliver the treatment under MAPS' clinically-tested PTSD treatment protocol prior to approval by Health Canada. The safety and efficacy of MDMA-assisted psychotherapy is currently under investigation. It has not yet been approved by Health Canada or the FDA, does not work for everyone, and carries risks even in therapeutic settings. These statements are no guarantee of future Health Canada or FDA approval or availability of MDMA-assisted psychotherapy. These statements necessarily involve known and unknown risks and uncertainties, which may cause actual outcomes to differ materially from projections. Is New 90 Day High Low • Nov 24
New 90-day high: €0.39 The company is up 216% from its price of €0.12 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 3.0% over the same period. Annuncio • Nov 19
Numinus Announces Compassionate Access Trial of Psilocybin-Assisted Psychotherapy for Substance Use Disorders Numinus Wellness Inc. has announced it will undertake a compassionate access clinical trial of psilocybin-assisted psychotherapy for substance use disorders. This study will enable the company to implement, test, and refine optimal protocols for the use of psilocybin-assisted psychotherapy for participants with a range of substance use disorders and will be conducted in collaboration with Syreon Corporation, a global contract research organization with expertise in conducting clinical trials across a broad range of chronic and complex diseases. The study will involve an initial 30 participants who will take part in a motivational enhancement psychedelic psychotherapy intervention with psilocybin. According to Health Canada's Special Access Programme, compassionate access single-arm open-label clinical trials can be incorporated into drug development planning to meet the needs of patients who are not eligible for enrollment in other pivotal trials and is one of Health Canada's preferred means for patients to access drugs that are not yet available on the market. The study builds upon a growing body of research demonstrating psilocybin-assisted psychotherapy's efficacy as a novel treatment for specific substance use disorders. A pilot study focusing on tobacco addiction at Johns Hopkins University found that 12 months after psilocybin therapy sessions, approximately 70% of participants remained completely abstinent from smoking and approximately 90% rated their psilocybin experience as among the most personally meaningful experiences of their lives. A study of psilocybin-assisted psychotherapy for alcohol use disorder at New York Universityhas also demonstrated major reductions in alcohol use. The evolving international regulatory landscape has opened the door to accessibility of psilocybin-assisted psychotherapy, and Numinus's compassionate access trial is expected to contribute to continued interest in expanding access. Numinus' compassionate access trial is the first in a series of planned projects and partnerships aimed at expanding access to MDMA for treatment of PTSD and psilocybin for treatment of substance use disorders. These implementation science initiatives will allow the company to refine clinical protocols and strategies for when these medications are approved for widespread use by regulating bodies. Is New 90 Day High Low • Oct 27
New 90-day high: €0.31 The company is up 94% from its price of €0.16 on 29 July 2020. The German market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 7.0% over the same period. Annuncio • Oct 15
Numinus Wellness Inc. Appoints Multidisciplinary Global Leaders to its General Advisory Council Numinus Wellness Inc. appointed multidisciplinary global leaders to its General Advisory Council. Members of the advisory council include: Jamie Wheal, Founder & Executive Director, Flow Genome Project; Ben Nemtin, Co-founder, The Buried Life; Dennis McKenna, Ethnopharmacologist, Co-founder of the Heffter Research Institute, and Founder of the McKenna Academy; Pamela Hadfield, Co-founder, HelloMD; and Nichol Bradford, Co-founder & Executive Director, Transformative Technology Lab and CEO, Willow Group. Drawing on experience across a broad range of specialities including psychedelic medicine, mental health advocacy, performance optimization, and digital healthcare, the multidisciplinary council will provide unique insight and guidance to support Numinus' mission of creating an ecosystem of health solutions centred on safe, evidence-based, accessible psychedelic-assisted psychotherapy. Is New 90 Day High Low • Oct 08
New 90-day high: €0.21 The company is up 4.0% from its price of €0.20 on 10 July 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 8.0% over the same period. Annuncio • Sep 26
Numinus Commences Psilocybe Mushroom Cultivation At Its Health Canada Licensed Laboratory Numinus Wellness Inc. announce it has begun cultivating Psilocybe mushrooms, for the purpose of psilocybin production, at its 7000 square-foot Health Canada licensed facility. Psilocybin-assisted psychotherapy is currently being studied as a treatment for a range of mental health conditions including depression, anxiety, and substance use disorders. Annuncio • Sep 11
Numinus Wellness Inc. has completed a Composite Units Offering in the amount of CAD 4 million. Numinus Wellness Inc. has completed a Composite Units Offering in the amount of CAD 4 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 16,000,000
Price\Range: CAD 0.25
Discount Per Security: CAD 0.023